Ivan Hyep Sells 28,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 28,000 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total transaction of $187,864.00.
• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.00, for a total transaction of $211,600.00.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.77 on Friday, reaching $28.91. The stock had a trading volume of 584,437 shares, compared to its average volume of 1,011,479. Bicara Therapeutics Inc. has a 12-month low of $9.47 and a 12-month high of $30.99. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -10.40 and a beta of -0.81. The firm’s fifty day moving average is $23.43 and its two-hundred day moving average is $20.10.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, research analysts forecast that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Deutsche Bank AG lifted its stake in shares of Bicara Therapeutics by 0.9% in the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares in the last quarter. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Mariner LLC grew its stake in Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after buying an additional 1,902 shares during the period. Invesco Ltd. increased its position in shares of Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after acquiring an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Bicara Therapeutics by 16.1% in the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BCAX. Morgan Stanley boosted their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Guggenheim initiated coverage on Bicara Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Finally, The Goldman Sachs Group increased their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.